BioCardia Inc. has announced that the University of Wisconsin School of Medicine and Public Health has enrolled its first patient in the ongoing Phase 3 CardiAMP HF II clinical trial. The trial is evaluating CardiAMP cell therapy for patients with ischemic heart failure who have elevated markers of heart stress, despite optimized medical therapy. Results from the study have not yet been presented, as the trial is still in progress.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-032289), on October 30, 2025, and is solely responsible for the information contained therein.